TriSalus Life Sciences Augments its TriNav Portfolio

TriSalus Life Sciences Inc. has expanded its TriNav product portfolio by introducing to market the TriNav FLX Infusion System, which features enhanced trackability to give interventional radiologists more options to select the right product for patients.¹

The TriNav FLX Infusion System retains the same trusted Pressure-Enabled Drug Delivery (PEDD) benefits as existing products but introduces an important advancement in design—the new system features twice the length of more flexible material at the distal end, allowing for easier navigation through more tortuous vessels. This enhancement is particularly beneficial for procedures where precise control and flexibility are required due to challenging peripheral vascular anatomy.

Key features of the TriNav FLX Infusion System include:

• Enhanced Trackability: The more flexible distal end provides improved navigation through challenging pathways.
• Reduction in Force: In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard TriNav design.¹

“We’re excited to further expand our TriNav portfolio with the introduction of the TriNav FLX Infusion System,” TriSalus Life Sciences CEO Mary Szela said. “With TriNav FLX, we now offer a comprehensive suite of advanced technologies designed to support interventional radiologists in navigating a wide range of peripheral vessel sizes and complexities. Our continued investment in portfolio innovation underscores our commitment to making pressure-enabled drug delivery accessible to more patients. Importantly, TriNav FLX is also eligible for reimbursement under HCPCS Code C8004 for simulation—or mapping—as well as C9797 for treatment procedures. This dual coverage allows clinicians to use TriNav FLX for both planning and delivery in radioembolization, supporting greater precision and continuity of care.”

TriSalus Life Sciences is an oncology-focused medical technology business developing disruptive drug delivery technology to improve therapeutic delivery for treating both oncologic and non-oncologic conditions. The company also is exploring the integration of the technology with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for various liver and pancreatic indications. TriSalus Life Sciences has developed an organ-specific platform designed to overcome two significant challenges preventing optimal delivery and performance of therapeutics: (i) high intratumoral pressure caused by tumor growth and collapsed vasculature, restricting the delivery of oncology therapeutics, and (ii) the immunosuppressive properties of liver and pancreatic tumor immune cells.

Reference
¹ Internal Test Report REP-0498; 28% reduction in forces to track through a benchtop tortuous model vs. TriNav